Blockchain Registration Transaction Record

Nutriband Advances Abuse-Deterrent Fentanyl Patch Toward FDA Filing

Nutriband updates on AVERSA™ FENTANYL abuse-deterrent patch development, new directors, FDA engagement, and 2026 plans for NDA filing and clinical studies.

The development of AVERSA™ FENTANYL addresses a critical public health issue: the opioid epidemic, which has caused widespread addiction and fatalities due to the abuse of potent drugs like fentanyl. By incorporating abuse-deterrent technology into a transdermal patch, this innovation could significantly reduce misuse and accidental exposure, potentially saving lives and easing the burden on healthcare systems. For patients with severe pain who legitimately require fentanyl, it offers a safer administration method, while for society, it represents a proactive step in combating drug diversion. The progress toward regulatory approval and extended patent protection also highlights the economic and therapeutic potential, making it relevant for investors, healthcare providers, and communities affected by opioid abuse.